Myriad Genetics (MYGN) Capital Expenditures Growth (3y) (2012 - 2026)
Myriad Genetics (MYGN) Capital Expenditures Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 16.58% |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | -6.49% |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | 93.09% |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | 10.06% |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 7.36% |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | -3.55% |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | -5.23% |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | -1.12% |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | 8.41% |
| 10 | Myriad Genetics | 300.99 Mn | 185.79 Mn | 127.00 Mn | -51.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -51.84% |
| Mar 31, 2026 | -38.75% |
| Dec 31, 2025 | -31.46% |
| Sep 30, 2025 | -45.92% |
| Jun 30, 2025 | -25.24% |
| Mar 31, 2025 | -5.60% |
| Dec 31, 2024 | 1.92% |
| Sep 30, 2024 | 5.27% |
| Jun 30, 2024 | 4.94% |
| Mar 31, 2024 | -1.91% |
| Dec 31, 2023 | 8.17% |
| Sep 30, 2023 | 17.03% |
| Jun 30, 2023 | 52.51% |
| Mar 31, 2023 | 98.60% |
| Dec 31, 2022 | 110.29% |
| Sep 30, 2022 | 132.96% |
| Jun 30, 2022 | 68.52% |
| Mar 31, 2022 | 26.67% |
| Dec 31, 2021 | 6.69% |
| Sep 30, 2021 | 32.15% |